Beta Bionics price target raised to $21 from $18 at Truist

Truist analyst Richard Newitter raised the firm’s price target on Beta Bionics (BBNX) to $21 from $18 and keeps a Buy rating on the shares. The stock should see strength and could regain some recently lost ground following a solid Q2 revenue and EPS beat driven by new patient start upside, the analyst tells investors in a research note. An accelerating pharmacy channel shift has even bigger positive out-year estimate implications, the firm added.